LabCentral Ignite’s Post

When choosing a CDMO, the stakes could not be higher. It's important to consider not only the capabilities and technical expertise that align with your project, there must be aligned values, and a shared commitment to open communication and partnership. Right from the start, Serán BioScience's teams are carefully considering your molecule profile, target product profile and business goals when developing a project plan. Whether you're dealing with solubility or permeability concerns or you have limited material available, our teams will leverage their experience and expertise to develop an appropriate formulation strategy to meet your program's unique needs. Find out how Serán can support your program, right from the start! https://hubs.li/Q02Dh6jv0 #CDMO #Partnership #drugformulation

🔔 M&A NEWS: In one of the biggest M&A deals involving AI-focused drug developers to date, Recursion (Nasdaq: RXRX) has entered into a definitive agreement to combine with Exscientia (Nasdaq: EXAI). 🤝 It was a real pleasure to support Recursion on this first stage of what will be a transformational transaction, working alongside colleagues from Wilson Sonsini and Clifford Chance. 🧬 This from Chris Gibson, Co-Founder and CEO of Recursion: “From our inception, we have been relentlessly focused on using technology and automation to decode biology and design and deliver the best treatments to patients in need. With this agreement, we intend to accelerate even more rapidly toward that shared goal – combining our high throughput target biology, foundation models, and supercomputing capabilities with Exscientia’s generative AI drug design, precision chemistry, and automated synthesis.” ⚖️ The combination is expected to be implemented through a scheme of arrangement under English law and is subject to the satisfaction of customary closing conditions, including receipt of regulatory approvals, approval of Exscientia shareholders, approval of Recursion’s stockholders and court sanction of the scheme. The transaction is expected to close by early 2025. 🍾 Huge congratulations to both companies. Link to the press release below. #mergersandacquisitions #artificialintelligence #technology #pharma #drugdiscovery

🔬 📈 Biotech investors and corporate development professionals We've just launched Gosset, the platform that provides insights about biotech assets. Try our demo here: https://lnkd.in/gK2mUiTm and comment on this post to get early access to the full version (or just to help us spread the word:)

🚀 Case Study Spotlight: How Edesa Biotech Builds Trust to Elevate Partnering Success 🤝 In the fast-paced world of biopharma business development, trust is the cornerstone of successful partnerships. In our latest partneringONE case study, we sat down with Leonardo Bonifacio, Director of Business Development Edesa Biotech, Inc., to uncover his top strategies for effective partnering and building long-term relationships. Edesa Biotech, a clinical-stage company developing therapies for inflammatory and immune-related diseases, has used partneringONE since 2015 to secure significant collaborations. Leo shares his Top 10 Partnering Tips, including: 💡Build Trust: Understand your partners’ needs and focus on long-term, mutually beneficial relationships. 🎯 Tailor Your Pitch: Personalize your message and show genuine interest in potential partners. 🔗 Focus on Quality: Target strategic companies and build a profile that clearly communicates your company’s value. 📅 Stay Organized: Effective follow-up and clear next steps keep partnerships moving forward. Partnering events are not just about meetings—they’re about relationships, insights, and new opportunities. Learn how Edesa Biotech continues to maximize their partnering efforts with partneringONE, and explore valuable tips for your next event! 📖 Read the full case study and start optimizing your partnering strategy: http://spr.ly/6047U4sCl #BiotechPartnerships #PartneringSuccess #Biopharma #BusinessDevelopment #TrustInPartnerships #EdesaBiotech #Collaboration #InnovationInHealthcare #LifeSciences #inlicensing #outlicensing #partnering #partneringONE #powerupyourpartnering #techscouting #connectionsthatcount

Great opening plenary panel to start the morning. Great feedback from Seqirus, Amgen, United Therapeutics, Intellia. My favorite question to listen to these leaders discuss was why choose NC over any other hub. Keys takeaways: Q: Why choose NC for your biopharma? -talent pool - not just in scientists but in supporting vendors -Quality of life for employees to enjoy their life and easier to start and raise families -cost of living/operating costs -economic incentives from visionary local leaders at the state, county, and state level -easy to pull workers from other hubs like Boston and San Fran -favorable geography with access to supply lines, airport, good weather, etc It’s great to hear the continuous growth of the RTP and surrounding NC areas (Wilmington included) #24tech

French biotech: disappointing post-IPO performance. Over the period between January 2012 and February 2024, the analysis of the performance of French biotechs is disastrous, with only Medincell having a share price higher than that of its IPO. There are many reasons for this, with many clinical and regulatory failures confirming the binary nature of this industry. The problem is that the likelihood of seeing the light at the end of the tunnel is low for many companies. Is the peak negative sentiment is behind or ahead of us?

In the fickle world of venture-backed biotech, the dual-track process is picking up steam. Explore an IPO, but also consider an M&A exit. Or, go the triple-track route: raise a crossover and prepare for a Wall Street debut while simultaneously building rapport with biopharma companies for a shot at an acquisition. “This is still a market where companies need to, in our view, explore any and all avenues to make sure that their product or their candidates can progress through the clinic as efficiently and quickly as possible and hopefully get into patients,” said Kevin Eisele. Companies like EyeBio, Escient, ProfoundBio and Mariana Oncology were likely IPO stories later this year, but were bought out first. Private biotechs are having their moment in the world of M&A. “There probably have to be more positive data readouts for some of the public stories to become of interest to big pharma again, but there’s plenty of high-quality private companies now for big pharma to look at that are clinical-stage, have generated positive clinical data and are also hot therapeutic areas,” said Daniel Parisotto, PhD. More below from my interviews with Kevin, Daniel, Jonathan Norris and Rachael Bushey, plus some insight from leaders at recent dual-trackers Carmot Therapeutics and HI-Bio. #biotech #pharma #biopharma #manda #mergersandacquisitions #dualtrack #ipo #nasdaq

Dealmaking has hit biopharma front and center this year. 2024 is off to a great start with all the M&A and BD deal announcements leading up to the J.P. Morgan Healthcare Conference. With all the trials and tribulations biotech founders go through, M&A shines as the bright light at the end of the tunnel. Of course the announcements are the tip of the iceberg. A milestone achieved after months of engagement to find the right fit and the right partner.   If you have been following the space or looking for a recap, here is a list of deals announced so far this month. Here's to hoping for many more successful M&A exits this year!   #biotech #biopharma #dealmaking #jpm2024

We’ve been following JPM Week closely, and we agree with the folks at STAT that dark skies are starting to clear for the biotech industry—and for biopharma specifically. December delivered good news for many companies, and we’ve seen a resulting spike in biopharma client hiring for the first time in 12 months. We expect that trend to continue in 2024. #biotech #biopharma #staffing #employment

Looking forward to this great panel discussion to kick-off Life Sciences Future!